Case against Gilead for de­lay­ing re­lease of safer HIV drug on sol­id ground, court rules

Gilead can be held re­spon­si­ble for putting off the re­lease of an HIV drug that it knew was safer than an­oth­er prod­uct it was al­ready sell­ing.

The rul­ing per­tains to a law­suit filed at the Su­pe­ri­or Court of San Fran­cis­co by 24,000 AIDS pa­tients who took Gilead’s treat­ments. In Au­gust 2023, Gilead ap­pealed to dis­miss the law­suit, which com­prised three claims.

The Cal­i­for­nia ap­pel­late court dis­missed two of the claims but on Tues­day, it de­cid­ed against dis­miss­ing the third. In do­ing so, “the court has up­end­ed es­tab­lished Cal­i­for­nia law,” a Gilead spokesper­son told End­points News in an email. Gilead will con­tin­ue to de­fend it­self and is eval­u­at­ing its apel­late op­tions, the spokesper­son added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER